Ignite Creation Date:
2024-05-05 @ 12:01 PM
Last Modification Date:
2024-10-26 @ 9:18 AM
Study NCT ID:
NCT00215813
Status:
AVAILABLE
Last Update Posted:
2024-04-12
First Post:
2005-09-16
Brief Title:
Ampligen in Chronic Fatigue Syndrome
Sponsor:
AIM ImmunoTech Inc
Organization:
AIM ImmunoTech Inc
Study Overview
Official Title:
An Open-Label Study Of Poly IPoly C12U AMPLIGEN in Patients With Severely Debilitating Chronic Fatigue Syndrome CFS
Status:
AVAILABLE
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is an open label study of Ampligen in patients with chronic fatigue syndrome
Detailed Description:
An Open-Label Study of Poly I Poly C12U Ampligen in Patients with Severely Debilitating Chronic Fatigue Syndrome CFSMyalgic Encephalomyelitis ME The FDA approved the study for cost recovery Patients enrolled in the study are responsible for costs related to the therapy eg drug cost infusion cost cost of supplies diagnostic and other laboratory testing
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None